Hansa Biopharma AB (publ) (STO:HNSA)
Sweden
· Delayed Price · Currency is SEK 29.34
-0.36 (-1.21%)
At close: Mar 9, 2026
Hansa Biopharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 701.08 | 405.28 | 732.06 | 1,496 | 651.34 | Upgrade
|
| Short-Term Investments | - | - | - | - | 237.62 | Upgrade
|
| Cash & Short-Term Investments | 701.08 | 405.28 | 732.06 | 1,496 | 888.96 | Upgrade
|
| Cash Growth | 72.99% | -44.64% | -51.07% | 68.31% | -35.47% | Upgrade
|
| Accounts Receivable | 53.87 | 144.97 | 78.03 | 42.96 | 9.71 | Upgrade
|
| Other Receivables | 35.52 | 17.49 | 15.73 | 24.22 | 13.53 | Upgrade
|
| Receivables | 89.4 | 162.46 | 93.76 | 67.18 | 23.24 | Upgrade
|
| Inventory | 6.13 | 2.61 | 1.51 | 0.97 | 0.24 | Upgrade
|
| Prepaid Expenses | - | 2.84 | 3.06 | 3.52 | 3.34 | Upgrade
|
| Other Current Assets | - | 12.24 | 24.76 | 36.85 | 26.56 | Upgrade
|
| Total Current Assets | 796.61 | 585.43 | 855.15 | 1,605 | 942.34 | Upgrade
|
| Property, Plant & Equipment | 13.35 | 17.88 | 27.07 | 35.84 | 41.71 | Upgrade
|
| Other Intangible Assets | 230.56 | 20.46 | 23.17 | 26.01 | 28.76 | Upgrade
|
| Long-Term Accounts Receivable | 126.25 | - | - | - | - | Upgrade
|
| Long-Term Deferred Charges | - | 176.88 | 112.65 | 20.85 | - | Upgrade
|
| Total Assets | 1,167 | 800.64 | 1,018 | 1,687 | 1,013 | Upgrade
|
| Accounts Payable | 66.29 | 37.62 | 86.97 | 62.48 | 53.36 | Upgrade
|
| Accrued Expenses | 121.14 | 97.89 | 116.54 | 100.32 | 78.22 | Upgrade
|
| Short-Term Debt | 136.87 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 8.28 | 7.68 | 7.5 | 7.17 | 6.89 | Upgrade
|
| Current Income Taxes Payable | 1.83 | 2.71 | 1.6 | 0.6 | - | Upgrade
|
| Current Unearned Revenue | - | 16.33 | 41.47 | 40.43 | 24.96 | Upgrade
|
| Other Current Liabilities | 76.26 | 93.45 | 66.91 | 53.71 | 7.79 | Upgrade
|
| Total Current Liabilities | 410.66 | 255.69 | 320.99 | 264.71 | 171.22 | Upgrade
|
| Long-Term Debt | 785.68 | 1,065 | 844.9 | 762.6 | - | Upgrade
|
| Long-Term Leases | 3 | 6.68 | 14.36 | 21.33 | 28.49 | Upgrade
|
| Long-Term Unearned Revenue | 1.61 | - | - | 29.5 | 47.02 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.26 | 0.17 | 0.37 | 0.41 | 0.43 | Upgrade
|
| Other Long-Term Liabilities | 49.71 | 63.3 | 5.3 | 5.95 | 8.08 | Upgrade
|
| Total Liabilities | 1,251 | 1,390 | 1,186 | 1,084 | 255.24 | Upgrade
|
| Common Stock | -84.13 | 67.81 | 55.03 | 55.03 | 46.34 | Upgrade
|
| Additional Paid-In Capital | - | 3,451 | 3,083 | 3,022 | 2,573 | Upgrade
|
| Retained Earnings | - | -4,110 | -3,303 | -2,471 | -1,860 | Upgrade
|
| Treasury Stock | - | - | -2.36 | -2.59 | -1.86 | Upgrade
|
| Comprehensive Income & Other | - | 0.94 | -0.41 | 0.01 | 0.13 | Upgrade
|
| Shareholders' Equity | -84.13 | -589.83 | -167.88 | 602.91 | 757.57 | Upgrade
|
| Total Liabilities & Equity | 1,167 | 800.64 | 1,018 | 1,687 | 1,013 | Upgrade
|
| Total Debt | 933.82 | 1,079 | 866.77 | 791.09 | 35.38 | Upgrade
|
| Net Cash (Debt) | -232.73 | -673.73 | -134.71 | 705.09 | 853.58 | Upgrade
|
| Net Cash Growth | - | - | - | -17.40% | -37.81% | Upgrade
|
| Net Cash Per Share | -2.87 | -10.72 | -2.56 | 15.70 | 19.19 | Upgrade
|
| Filing Date Shares Outstanding | 101.76 | 67.81 | 52.67 | 52.44 | 44.47 | Upgrade
|
| Total Common Shares Outstanding | 101.76 | 67.81 | 52.67 | 52.44 | 44.47 | Upgrade
|
| Working Capital | 385.95 | 329.74 | 534.16 | 1,340 | 771.12 | Upgrade
|
| Book Value Per Share | -0.83 | -8.70 | -3.19 | 11.50 | 17.03 | Upgrade
|
| Tangible Book Value | -314.7 | -610.29 | -191.05 | 576.9 | 728.81 | Upgrade
|
| Tangible Book Value Per Share | -3.09 | -9.00 | -3.63 | 11.00 | 16.39 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.